USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| - | Jun 30, 2022 | - | - | - |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| - | Jun 30, 2022 | - | - | - |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $-1.56 | $-3.63 | $0.85 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 1 | $5.50 | $5.69 | $7.94 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $208.87M | $33.96M | $516.24M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Apr 15, 2021 | Mar 2021 | $-0.61 | $-0.39 | 36.90% |
| Dec 31, 2020 | Dec 2020 | $-0.61 | $-0.38 | 37.70% |
| Nov 30, 2020 | Sep 2020 | $-0.88 | $-0.29 | 67.55% |
| Aug 14, 2020 | Jun 2020 | $-54.37 | $-0.29 | 99.47% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Dec 31, 2020 | Dec 2020 | $-2.36 | $-0.96 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Apr 15, 2021 | Mar 2021 | $11.32M | - | - |
| Dec 31, 2020 | Dec 2020 | $7.31M | $6.04M | 0.83% |
| Nov 30, 2020 | Sep 2020 | $6.25M | $5.16M | 0.83% |
| Aug 14, 2020 | Jun 2020 | $3.77M | - | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Dec 31, 2020 | Dec 2020 | $59.56M | $48.87M | -17.94% |
Curevac's previous earnings date was Apr 13, 2022 for its fiscal quarter ended Mar 31, 2022.
Curevac's previous annual earnings date was Dec 31, 2020 for its fiscal year ended Dec 31, 2020.
CVAC's earnings per share (EPS) was $-0.96.
Revenues were $48.87M, worse than the forecast of $59.56M by -17.94%, and up by 180.61% from previous year's revenue.
The company reported a net income of $-129.12M.
Curevac reported a free cash flow of $475.05M for its fiscal year, compared to $-99.19M a year ago.
The company ended the fiscal year with $55.28M in total debt, a decrease of -30.16% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
